Deck 39: Alzheimers Disease in Women

Question 1

High intake of _____ can lower the risk of cardiovascular disease and potentially lower the risk of AD through vascular mechanisms.

A) trans fats
B) saturated fats
C) hydrogenated fats
D) n-3 polyunsaturated fatty acids

Answer 1

D

Question 2

Which antioxidant blocks the creation of nitrosamines through the reduction of nitrites, and may also affect catecholamine synthesis?

A) vitamin C
B) vitamin E
C) selenium
D) coenzyme Q10

Answer 2

A

Question 3

Which of the following is a behavioral manifestation of moderate AD?

A) apathy
B) depression
C) agitation
D) frequent incontinence

Answer 3

C

Question 4

Which of the four genes clinically available for genetic testing for AD is a susceptibility gene that is neither sufficient nor necessary to cause AD?

A) APOE
B) PSEN1
C) PSEN2
D) APP

Question 5

What two key genes are involved in the peripheral synthesis of estrogens?

A) ESR1 and ESR2
B) CYP17 and CYP19
C) BRCA1 and BRCA2
D) KRT5 and KRT14

Question 6

Which statement about estrogen is correct?

A) It decreases cholinergic activity.
B) It has oxidizing properties.
C) It promotes the survival of cholinergic neurons.
D) It inhibits the nonamyloidogenic metabolism of the amyloid precursor protein.

Question 7

Moderate alcohol consumption in human beings is related to _____.

A) more silent brain infarcts
B) less brain atrophy
C) greater risk of clinical stroke
D) less white-matter disease

Question 8

All studies of AD have shown a significantly higher incidence in women compared with men.

Question 9

AD currently affects 1 in 8 men and women over age 65.

Question 10

Research data indicates that lower lifetime endogenous estrogen exposure increases the risk of dementia in the Down Syndrome population.

Question 11

Data from three randomized, placebo-controlled trials of unopposed estrogen therapy on episodic verbal memory in women younger than age 65 indicates that estrogen alone either enhances or has no effect on verbal memory in younger women during short-term follow-up.

Question 12

Structural neuroimaging is used to verify an AD diagnosis.

Question 13

What is the usual disease duration in AD?

Question 14

List three of the brain changes which, along with the presence of dementia, are required for a diagnosis of AD.

Question 15

How do cholinesterase inhibitors enhance cholinergic function, and why is this beneficial to AD patients?